This story originally ran on Oct. 8.
Life Technologies division Invitrogen has decided not to manufacture or sell the protein-standard mixture it developed in collaboration with the Human Proteome Organization.
In the meantime, HUPO is in negotiations with another vendor to commercialize the mixture developed to serve as a benchmark for the mass spectrometry-based proteomics community. Officials declined to identify the vendor.
HUPO first revealed that Invitrogen had chosen not to commercialize the 20-protein mixture at its annual meeting in Toronto last month, saying Invitrogen could not meet the organization's minimum requirement of 95-percent purity without it being cost-prohibitive.
This week, Invitrogen confirmed its decision in an e-mail to ProteoMonitor. Paul Predki, vice president of molecular biology reagents R&D for Life Tech, said the samples and protocols have been transferred to HUPO "so that [HUPO] can support the standards independently."
He did not address why Invitrogen chose to pull out of the agreement, and the company said it would have no further comment.
The protein-standard sample was developed by the two partners to serve as a benchmark by which researchers can measure the performance of their instruments [See PM 07/21/06]. The mixture was also used by HUPO in a study evaluating the ability of laboratories to characterize the proteins in the samples and identify common bottlenecks.
In a study published in May, seven out of 27 labs – 24 research labs and three commercial vendors – were able to identify all 20 proteins [See PM 05/21/09].